Health authorities have initiated a vaccination campaign aimed at protecting approximately one million teenagers and young adults against meningitis B infection. The programme focuses on individuals deemed at highest immediate risk and represents a response to ongoing concerns about the prevalence of meningococcal disease.
Meningitis is an infection affecting the protective membranes surrounding the brain and spinal cord. While it can impact people of any age, it occurs most frequently in babies, young children, teenagers, and young adults. The condition can develop from either bacterial or viral causes, with bacterial meningitis presenting greater severity than its viral counterpart. Bacterial meningitis may progress to blood poisoning or sepsis and can damage brain tissue, a condition termed invasive meningitis. Meningococcal group B bacteria is responsible for most severe cases of meningococcal disease in the UK, with 378 cases of invasive meningococcal disease documented in the period 2024-2025.
Symptoms of meningitis can emerge suddenly and include high fever, severe headache, neck stiffness, rashes that do not blanch when pressed, vomiting, diarrhea, muscle and joint pain, light sensitivity, cold extremities, seizures, and altered mental status. Prompt medical attention is critical, as early treatment can be lifesaving.
Two primary vaccines provide protection against major causes of meningitis. The MenACWY vaccine protects against four bacterial groups and is offered to teenagers aged 14, with free access available until age 25 for those who missed vaccination. The MenB vaccine protects against group B bacteria and is recommended for infants beginning at eight weeks. Additional vaccines against other pathogens that can cause meningitis-related complications are also available through routine immunisation programmes.
Transmission occurs through close personal contact, with bacteria spread via respiratory droplets from coughs, sneezes, and saliva exchange. The targeted vaccination programme offers two free doses to Year 13 pupils and individuals under 25 beginning university or residential further education this autumn. Experts note this population faces elevated risk due to shared living arrangements, particularly as disease incidence peaks from October to November annually.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI